{"id":"genomic-driven-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Chemotherapy-related toxicity (variable by selected agent)"},{"rate":null,"effect":"Hematologic toxicity"},{"rate":null,"effect":"Gastrointestinal toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach uses comprehensive genomic analysis of a patient's tumor to identify specific mutations, gene expression patterns, and molecular signatures that predict chemotherapy sensitivity. Treatment selection is then personalized based on these genomic findings, aiming to match the most effective chemotherapy agents to each patient's unique tumor biology, thereby improving response rates while minimizing unnecessary exposure to ineffective drugs.","oneSentence":"Genomic-driven chemotherapy selects and administers chemotherapy agents based on individual tumor genomic profiling to optimize treatment efficacy and reduce toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:04.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors with genomic profiling-guided chemotherapy selection"}]},"trialDetails":[{"nctId":"NCT07106632","phase":"PHASE3","title":"Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04-01","conditions":"Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer","enrollment":3380},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT06244069","phase":"","title":"Clonal Hematopoiesis in Giant Cell Arteritis","status":"NOT_YET_RECRUITING","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2024-03","conditions":"Giant Cell Arteritis, Temporal Arteritis, Clonal Hematopoiesis of Indeterminate Potential","enrollment":326},{"nctId":"NCT01648517","phase":"PHASE2","title":"Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-07-27","conditions":"Non-small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT01180335","phase":"PHASE3","title":"Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-01","conditions":"Breast Cancer","enrollment":303}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Genomic driven chemotherapy","genericName":"Genomic driven chemotherapy","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Genomic-driven chemotherapy selects and administers chemotherapy agents based on individual tumor genomic profiling to optimize treatment efficacy and reduce toxicity. Used for Solid tumors with genomic profiling-guided chemotherapy selection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}